• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Screening of inhibitors for anchorage-independent tumor cell growth from microbial metabolites and their application in cancer chemotherapy

Research Project

Project/Area Number 14560083
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Bioproduction chemistry/Bioorganic chemistry
Research InstitutionToyama Prefectural University

Principal Investigator

IGARASHI Yasuhiro  Toyama Prefectural University, Department of Engineering, Associate Professor, 工学部, 助教授 (20285159)

Project Period (FY) 2002 – 2003
Project Status Completed (Fiscal Year 2003)
Budget Amount *help
¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2003: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 2002: ¥500,000 (Direct Cost: ¥500,000)
Keywordsantitumor agent / anchorage-independent growth / screening / microbial metabolite / 足場比依存性増殖阻害物質
Research Abstract

Inhibitors for anchorage-independent growth of tumor cells were screened from microbial secondary metabolites. Five hundred strains of actinomycetes and one hundred strains of fungi were cultured in liquid medium and the 1-butanol extracts were subjected to the screening. One actinomycete and one fungus showed potent inhibitory activity against the anchorage-independent growth of human colon tumor DLD-1 cells. The active compounds were isolated from the culture broth by chromatography using HPLC analysis and bioassay.
From the actinomycete, a novel antitumor compound TT2149-C was isolated. The producing-strain, was identified as Streptomyces thermoviolaceus TP-A0648 by taxonomic studies. TT2149-C is an analog of spicamycin, which was isolated from Streptomyces sp. as an antitumor antibiotic. TT2149-C inhibited the anchorage-independent growth of DLD-1 cells with the IC_<50> of 29 nM whereas it inhibited the anchorage-dependent growth with. the IC_<50> of 68 nM. TT2149-C showed very pote … More nt cytocidal activity against a variety of human cancer cell lines with the IC50 of 0.1 to 120 nM.
A novel antitumor compound anicequol was isolated from the fungus Penicillium aurantiogriseum TP-F0213. The structure of anicequol was confirmed as (3β, 5α, 7β, 11β, 16β-16-acetoxy-3,7,11-trihydroxyergost-22-en-6-one by X-ray diffraction of bis-p-bromobenzoate of anicequol. Anicequol inhibited the anchorage-independent growth of DLD-1 cells with the IC_<50> of 1.2 μM whereas it inhibited the anchorage-dependent growth with the IC_<50> of 40 μM. The selectivity of anicequol is superior to that of TT2149-C. Anicequol did not show activity against protein kinases, farnesyl transferase and tublin function. Structure-activity relationship (SAR) of anicequol, was studied using synthetic derivatives. Acetylation of 3-and 7-hydroxy groups resulted in the loss of activity. However, the acetylation of 3-hydroxy group reduced the toxicity to the anchorage-dependent growth but enhanced the cytotoxicity to the anchorage-independent growth. SAR of anicequol will be studied furthermore. Less

Report

(3 results)
  • 2003 Annual Research Report   Final Research Report Summary
  • 2002 Annual Research Report
  • Research Products

    (2 results)

All Other

All Publications (2 results)

  • [Publications] Y.Igarashi: "Anicequol, a novel inhibitor for anchorage-independent growth of tumour cells from Penicillium aurantiogriseum Dierckx TP-F0213"Journal of Antibiotics. Vol.55. 371-376 (2002)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      2003 Final Research Report Summary
  • [Publications] Y.Igarashi et al.: "Anicequol, a novel inhibitor for anchorage-independent growth of tumour cells from Penicillium aurantiogriseum Dierckx TP-F0213"Journal of Antibiotics. Vol.55. 371-376 (2002)

    • Related Report
      2002 Annual Research Report

URL: 

Published: 2002-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi